Evidence map›Paper›PMID 35110331›Full record

ArticleAnnals of the rheumatic diseases2022

EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.

George C Drosos, Daisy Vedder, Eline Houben, Laura Boekel, Fabiola Atzeni, Sara Badreh, Dimitrios T Boumpas, Nina Brodin, Ian N Bruce, Miguel Ángel González-Gay and 18 more

Open access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Annals of the rheumatic diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 198 papers, 20 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
198citing papers in PubMed, 20 pooled it
54.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

198 citing papers in PubMed, 20 syntheses or guidelines pooled it, 338 citations in OpenAlex.

  1. Pooled it
  2. Guideline
  3. Pooled it
  4. Guideline
  5. Guideline
  6. Pooled it
  7. [Diagnosis and treatment of ANCA-associated vasculitis : SHORT VERSION of the S3 guideline of the German Society for Rheumatology and Clinical Immunology e. V. (DGRh) and German Society for Internal Medicine e. V. (DGIM), German Society for Nephrology e. V. (DGfN), German Society for Otorhinolaryngology and Head and Neck Surgery e. V. (DGHNO-KHC), German Ophthalmological Society e. V. (DOG), German Society for Neurology e. V. (DGN), German Society for Pneumology and Respiratory Medicine e. V. (DGP), German Society for Pathology e. V. (DGP), German Radiological Society, Society for Medical Radiology e. V. (DRG), Federal Association of German Pathologists, Federal Kidney Association e. V., German Rheumatism League Federal Association e. V.]Zeitschrift fur Rheumatologie · 2025
    Guideline
  8. Guideline
  9. Pooled it
  10. Guideline
  11. Pooled it
  12. Pooled it
  13. Guideline
  14. Guideline
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Guideline
  19. Pooled it
  20. Pooled it

138 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 19 institutions in 11 countries.

George C Drosos *First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece.ORCID http://orcid.org/0000-0001-7987-9588
Daisy Vedder *Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0003-1715-9555
Eline Houben *Department of Internal Medicine, Northwest Clinics, Alkmaar, The Netherlands.
Laura BoekelReade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.ORCID http://orcid.org/0000-0001-5473-7786
Fabiola AtzeniRheumatology Unit, Department of Internal Medicine, University of Messina, Messina, Italy.
Sara BadrehEULAR Patient Research Partner, Brussels, Belgium.
Dimitrios T Boumpas4th Department of Internal Medicine, "Attikon" University Hospital, Athens, Greece.ORCID http://orcid.org/0000-0002-9812-4671
Nina BrodinDivision of Physiotherapy, Department of Neurobiology, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden.
Ian N BruceCentre for Epidemiology Versus Arthritis, Centre for Musculoskeletal Research, University of Manchester, Manchester, UK.
Miguel Ángel González-GayRheumatology Division, Hospital Universitario Marqués de Valdecilla and University of Cantabria, Santander, Spain.ORCID http://orcid.org/0000-0002-7924-7406
Søren JacobsenCopenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-5654-4993
György KerekesIntensive Care Unit, Department of Medicine, University of Debrecen, Debrecen, Hungary.
Francesca MarchioriEULAR Patient Research Partner, Rome, Italy.
Chetan MukhtyarRheumatology Department, Norfolk and Norwich University Hospital, Colney Lane, UK.ORCID http://orcid.org/0000-0002-9771-6667
Manuel Ramos-CasalsDepartment of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Barcelona, Spain.
Naveed SattarInstitute of Cardiovascular and Medical Sciences, University of Glasgow, Glasgow, UK.
Karen SchreiberEMEUNET member, Danish Hospital for Rheumatic Diseases, Sonderburg, Denmark.
Savino SciasciaEMEUNET member, CMID-Nephrology, San Giovanni Bosco Hospital, University of Torino, Torino, Italy.ORCID http://orcid.org/0000-0003-1266-9441
Elisabet SvenungssonDepartment of Medicine, Rheumatology Unit, Karolinska Institutet and Karolinska University Hospital, Stockholm, Sweden.ORCID http://orcid.org/0000-0003-3396-3244
Zoltan SzekaneczDepartment of Rheumatology, University of Debrecen Faculty of Medicine, Debrecen, Hungary.ORCID http://orcid.org/0000-0002-7794-6844
Anne-Kathrin TauscheDepartment of Rheumatology, University Clinic Carl Gustav Carus at the TU Dresden, Dresden, Germany.
Alan TyndallDepartment of Rheumatology, University of Basel, Basel, Switzerland.
Vokko van HalmDepartment of Cardiology, Amsterdam University Medical Center, location VU University medical center, Amsterdam, The Netherlands.
Alexandre VoskuylDepartment of Rheumatology and Clinical Immunology, Amsterdam UMC, Vrije Universiteit, Amsterdam, The Netherlands.
Gary J MacfarlaneDepartment of Public Health, NHS Grampian, Aberdeen, UK.ORCID http://orcid.org/0000-0003-2322-3314
Michael M WardIntramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA.ORCID http://orcid.org/0000-0003-1857-9367
Michael T Nurmohamed *Reade, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands.
Maria G Tektonidou *First Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece mtektonidou@gmail.com.ORCID http://orcid.org/0000-0003-2238-0975
National and Kapodistrian University of Athens · GRReade · NLUniversity of Debrecen · HUAmsterdam University Medical Centers · NLDanderyds sjukhus · SEKarolinska University Hospital · SEManchester Academic Health Science Centre · GBNational Institutes of Health · USNHS Grampian · GBNorfolk and Norwich University Hospital · GBNorthwest Hospital · USOspedale San Giovanni Bosco · ITUniversidad de Cantabria · ESUniversitat de Barcelona · ESUniversity Hospital Carl Gustav Carus · DEUniversity of Basel · CHUniversity of Copenhagen · DKUniversity of Glasgow · GBUniversity of Messina · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo develop recommendations for cardiovascular risk (CVR) management in gout, vasculitis, systemic sclerosis (SSc), myositis, mixed connective tissue disease (MCTD), Sjögren's syndrome (SS), systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS).

methodsFollowing European League against Rheumatism (EULAR) standardised procedures, a multidisciplinary task force formulated recommendations for CVR prediction and management based on systematic literature reviews and expert opinion.

resultsFour overarching principles emphasising the need of regular screening and management of modifiable CVR factors and patient education were endorsed. Nineteen recommendations (eleven for gout, vasculitis, SSc, MCTD, myositis, SS; eight for SLE, APS) were developed covering three topics: (1) CVR prediction tools; (2) interventions on traditional CVR factors and (3) interventions on disease-related CVR factors. Several statements relied on expert opinion because high-quality evidence was lacking. Use of generic CVR prediction tools is recommended due to lack of validated rheumatic diseases-specific tools. Diuretics should be avoided in gout and beta-blockers in SSc, and a blood pressure target <130/80 mm Hg should be considered in SLE. Lipid management should follow general population guidelines, and antiplatelet use in SLE, APS and large-vessel vasculitis should follow prior EULAR recommendations. A serum uric acid level <0.36 mmol/L (<6 mg/dL) in gout, and disease activity control and glucocorticoid dose minimisation in SLE and vasculitis, are recommended. Hydroxychloroquine is recommended in SLE because it may also reduce CVR, while no particular immunosuppressive treatment in SLE or urate-lowering therapy in gout has been associated with CVR lowering.

conclusionThese recommendations can guide clinical practice and future research for improving CVR management in rheumatic and musculoskeletal diseases.

Indexed as

Antiphospholipid SyndromeCardiovascular DiseasesGoutLupus Erythematosus, SystemicMixed Connective Tissue DiseaseMusculoskeletal DiseasesMyositisRheumatic DiseasesScleroderma, SystemicSjogren's SyndromeVasculitisHeart Disease Risk FactorsHumansRisk FactorsUric AcidUric Acidantiphospholipid syndromeautoimmune diseasescardiovascular diseaseslupus erythematosussystemicsystemic vasculitis

Identifiers

PMID35110331
OpenAlexW4210613863

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.